Compare STOK & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STOK | WD |
|---|---|---|
| Founded | 2014 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2019 | 2010 |
| Metric | STOK | WD |
|---|---|---|
| Price | $36.53 | $50.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $39.20 | ★ $78.33 |
| AVG Volume (30 Days) | ★ 687.2K | 239.8K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 5.42% |
| EPS Growth | ★ 92.73 | N/A |
| EPS | N/A | ★ 1.64 |
| Revenue | $184,420,000.00 | ★ $1,234,306,000.00 |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | $77.49 | $7.79 |
| P/E Ratio | ★ N/A | $30.60 |
| Revenue Growth | ★ 404.50 | 8.99 |
| 52 Week Low | $8.30 | $42.12 |
| 52 Week High | $40.22 | $90.00 |
| Indicator | STOK | WD |
|---|---|---|
| Relative Strength Index (RSI) | 58.53 | 63.66 |
| Support Level | $30.34 | $42.34 |
| Resistance Level | $39.00 | $66.25 |
| Average True Range (ATR) | 1.77 | 1.44 |
| MACD | 0.34 | 1.06 |
| Stochastic Oscillator | 84.76 | 94.34 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.